The A+ Industrial Innovation R&D Program

HuniLihe is awarded in 2017 with a research grant of Taiwan government A+ program for preclinical development of HuL001 in multiple sclerosis.  The aim of this government’s A+ Program is to encourage and guide businesses to invest in high value-adding cutting-edge industrial technologies and to help biotech company get involved in innovation, development, and research programs.  It is a highly prestigious award and a symbol of recognition to our innovative technologies.